Pharmaceutical Industry Profits This Year By 27% Of The Pre
April 22 at the “Sixteenth China Medical Marketing Summit”, the experts expect the pharmaceutical industry’s profit growth this year will reach 27%, and, with government investment to increase and decrease the rate of health insurance fund balance, China’s pharmaceutical market will usher in Medicare spending and consumption of drugs “heavy volume.”
Despite the industry growth rate of long-term stability to the good, but in the export balance of trade and production, the pharmaceutical industry faces more trade frictions, excess capacity and other potential crisis.
Medicare spending by 33 billion yuan to be
Chinese Medical Association executive vice president of business management, said in Matilda, in the relevant departments of the promotion, my medical insurance fund savings rate will continue to reduce, in 2010 from 20% in 2009 down to 15%, a result, will increase health care Insurance Consumer 33.0 billion.
Secondly, since the new rural cooperative fund-raising standards of this year increased to reach 150 yuan per person per year, so in 2009 than the 100 yuan per person per year to increase the level of total investment 41.5 billion, of which, pharmaceutical spending increase of about 30,000,000,000 yuan. In addition, urban residents in the new rural cooperative medical insurance and hospital reimbursement policy areas will reach 60% this year, the proportion of urban workers will increase hospital reimbursement in developed cities, reimbursement will be higher.
This year’s increase government input and the pharmaceutical industry to make people excited. At Matilda said 2011,2012 medical reform in the relevant government investment is also expected to continue to increase.
Data show that in 2009, pharmaceutical industrial output value exceeded 1 trillion yuan for the first time, specific about 1.0382 trillion yuan, the pharmaceutical industry topped 100 billion yuan total profit, the pharmaceutical industry export delivery value of 100 billion yuan the first time.
For 2010 the development prospects of the pharmaceutical industry, medical experts, the year 2010 industrial production grew more than 25% annual profit growth above 27% of industrial, export delivery value growth of about 10%.
The next four years, China’s pharmaceutical market will maintain an average annual growth rate of more than 20%, in 2013 on the contribution of global pharmaceutical market growth rate will reach 21%.
Around the industry this year, a potential danger
Although the macro-level, industry is expected to optimistic, but micro-level, industry is facing many potential short-term crisis.
At Matilda said that from 2009 the current situation of pharmaceutical exports, exports of chemical raw and agents have not yet fully recovered from the international economic situation into account, the overall pharmaceutical export performance has also not optimistic about the growth momentum in export volumes over weak. In addition, there are increasing signs of trade friction. As the renminbi appreciation expectations, which give the export-oriented manufacturer of pharmaceutical products bring more selling pressure.
From the perspective of domestic situation, whether tender or delivery of medicines, there are more serious local protectionism is not conducive to the pharmaceutical market in the whole country to achieve fair competition.
Statistics show that in 2009, more than 7,000 pharmaceutical enterprises in China, the total increased by 10% year on year, of which the number of medical devices increased by 253 companies, an increase of 27%, 118 health material enterprises to increase year on year increase of more than 20%. To Matilda that this current government advocacy to improve the industry concentration a little departure from the idea.
This year, beginning July 1, the existing pharmaceutical companies will begin to implement “the pharmaceutical industry, water pollution discharge standards”; also in 2010 edition of “Chinese Pharmacopoeia” will be put into implementation on July 1, Chinese herbs, Chinese Herbal Medicine, Chinese patent medicine and standards of traditional Chinese medicine extracts increased dramatically. This means that pharmaceutical companies to bring energy saving, cost pressure will increase significantly.
In addition, some sub-industry overcapacity, the shadow will be long-term difficulties, and even more serious. For example, currently only five sales of large domestic pharmaceutical production line infusion of more than 113, which will undoubtedly lead to a large infusion industry becoming more competitive, industry consolidation will go in depth.
Matilda forecast in 2010, foreign-funded enterprises will be a lot of drugs and general medical equipment Jiaru Pu competition, the stock of companies on the enormous pressure of competition.
I am an expert from China Manufacturers, usually analyzes all kind of industries situation, such as wholesale dried herbs , aloe vera processing.
Processing your request, Please wait....
